Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
The Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis (0476-265)
- First Posted Date
- 2004-09-24
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1992
- Registration Number
- NCT00092118
Antihypertensive Efficacy and Safety of Approved Drugs in Japanese Patients With Essential Hypertension (Banyu Study)(0954A-302)
Phase 3
Completed
- Conditions
- Hypertension
- First Posted Date
- 2004-09-24
- Last Posted Date
- 2022-02-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 840
- Registration Number
- NCT00092209
Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Drugs in Patients With Elevated Cholesterol Levels (0653A-058)
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- First Posted Date
- 2004-08-30
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 2815
- Registration Number
- NCT00090298
Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure (0954-948)
- First Posted Date
- 2004-08-27
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 3834
- Registration Number
- NCT00090259
Cholesterol Lowering Level of MK0653A+Simvastatin in Patients With Hypercholesterolemia and Atherosclerotic or Coronary Vascular Disease (0653A-806)(COMPLETED)
Phase 3
Completed
- Conditions
- HypercholesterolemiaAtherosclerotic DiseaseCoronary Disease
- First Posted Date
- 2004-08-27
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 435
- Registration Number
- NCT00090168
Study of MK0663 in Patients With Chronic Low Back Pain (0663-806)(COMPLETED)
Phase 4
Completed
- Conditions
- Chronic Low Back Pain
- First Posted Date
- 2004-08-27
- Last Posted Date
- 2022-02-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 401
- Registration Number
- NCT00090181
Montelukast in Exercise-Induced Bronchospasm - 2004 (0476-275)
Phase 3
Completed
- Conditions
- Asthma, Exercise-Induced
- First Posted Date
- 2004-08-26
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 62
- Registration Number
- NCT00090142
EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED)
Phase 3
Completed
- Conditions
- Acute Coronary SyndromeMyocardial Ischemia
- Interventions
- Drug: Eptifibatide (Integrilin)Drug: Placebo
- First Posted Date
- 2004-08-19
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 9406
- Registration Number
- NCT00089895
An Investigational Drug Study to Treat Respiratory Symptoms Associated With Respiratory Syncytial Virus (RSV) Bronchiolitis (0476-272)
Phase 3
Completed
- Conditions
- Bronchiolitis
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1125
- Registration Number
- NCT00076973
Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)
Phase 4
Completed
- Conditions
- Rhinitis, Allergic, SeasonalAsthma
- Interventions
- First Posted Date
- 2003-10-10
- Last Posted Date
- 2022-02-07
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 188
- Registration Number
- NCT00070707
© Copyright 2025. All Rights Reserved by MedPath